Concepedia

Amir T. Fathi

AT

140

Publications

14.2K

Citations

53

H-Index

2006

Active since

Affiliations

Massachusetts General Hospital(Current)

Harvard University

Dana-Farber Cancer Institute

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Amir T. Fathi is an author at Massachusetts General Hospital specializing in medicine, oncology, and hematology.

ORCID

Top concepts

Publications per year

2006–2024

140

Publications

140

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.4K citations · Full text

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton et al. · New England Journal of Medicine · 2018 · 1.4K citations · Full text

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion

Rui Su, Lei Dong, Yangchan Li et al. · Cancer Cell · 2020 · 742 citations · Full text

, , +8

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud et al. · Journal of the National Comprehensive Cancer Network · 2017 · 651 citations · Full text

, , +14

Rows per page

1–5 of 140